Kimberly-Clark Beats Earnings Estimates as China Sales Dip
Direct answer
Kimberly-Clark beat profit expectations in the third quarter of 2026, but its sales slipped. Adjusted earnings were $1.70 per share, above the $1.66 estimate tracked by Zacks. Net sales were $4.13 billion, down 0.4 percent from a year earlier. The weak spot was China, where false claims about diaper quality on social media hurt demand, and the bright spot was the completed purchase of Kenvue, the maker of Tylenol.
What happened
Kimberly-Clark, the maker of Huggies diapers and Kleenex tissues, reported its third quarter results on Thursday, November 5, 2026, for the quarter ended September 30.
The headline profit number looked very strong, but it needs care. Net income attributable to Kimberly-Clark jumped to $1.79 billion, or $5.37 per share, from $446 million, or $1.34 per share, a year earlier. That jump came mostly from a $1.4 billion gain linked to the completion of a deal involving its International Family Care and Professional business. Strip out that one-off gain and other special items, and adjusted earnings were $1.70 per share, down 6.6 percent from $1.82 a year earlier, but still above estimates. On a continuing operations basis, adjusted earnings per share rose 17.2 percent, helped by lower interest costs and a lower tax rate.
Sales told a softer story. Net sales edged down 0.4 percent to $4.134 billion, and organic sales, which strip out currency moves and deals, fell 1.3 percent. The company said about 270 basis points of that fall came from the disruption in China. Adjusted operating profit fell 0.9 percent to $677 million, and adjusted gross margin fell 130 basis points to 35.5 percent, as prices fell 1.1 percent while input costs and supply chain spending rose.
By region, North America held up. Sales there rose 0.9 percent to $2.74 billion, with volumes up 2 percent. International Personal Care sales fell 2.8 percent to $1.40 billion, and its operating profit fell 32.7 percent, as organic sales in the segment dropped 4.6 percent, mostly because of China.
The company also confirmed it completed its roughly $40 billion acquisition of Kenvue on November 2, 2026, and it expects about $2.1 billion in annual run-rate synergies from combining the two businesses. It kept its 2026 outlook unchanged.
Why it matters for beginners
This is a useful example of why one profit number rarely tells the whole story. The reported profit of $5.37 per share looks like a huge jump, but most of it came from a one-off gain, not from selling more diapers and tissues. The adjusted figure of $1.70 per share is the better guide to how the underlying business performed, and even that fell from a year earlier.
It also shows how a single market can drag a global company. A social media storm in China cut organic sales by more than two percentage points for the whole company, even though North America grew. When one country or one product line matters a lot, a local problem can show up in the global result. Our guide to what risk means in investing explains this kind of single company risk in simple terms.
Finally, the Kenvue deal matters because it changes what Kimberly-Clark is. Buying a large consumer health business adds new brands and new debt, and the promised $2.1 billion in synergies will take time to appear. The company kept its full year outlook, which suggests management still expects steady, not fast, growth.
What to watch next
First, watch whether China demand recovers. The company blamed false claims about diaper quality, and if shoppers return, the drag on organic sales should fade. If it lingers, it will keep weighing on results.
Second, watch the Kenvue integration. Investors will look for signs that the combined company is actually saving money and growing, rather than just getting bigger.
Third, watch the full year outlook. Kimberly-Clark still expects 2026 organic sales growth about 100 basis points below category growth of around 1.7 percent, with adjusted operating profit growing at a mid-single-digit rate and adjusted earnings from continuing operations growing at a high-single-digit rate. Any change to that outlook in the next update would be a signal worth noting.
FAQ
Did Kimberly-Clark beat expectations?
Yes, on adjusted profit. Adjusted earnings of $1.70 per share beat the $1.66 consensus estimate tracked by Zacks. Sales of $4.13 billion were slightly below the $4.15 billion Zacks estimate, though broadly in line with estimates compiled by LSEG.
Why did sales fall if profit beat estimates?
Sales fell 0.4 percent because organic sales dropped 1.3 percent, mainly on the China disruption and retailer stock changes in North America. Profit beat estimates because lower interest costs and a lower tax rate lifted adjusted earnings from continuing operations by 17.2 percent.
What happened in China?
False claims about the quality of its diapers spread on social media in China, and demand fell. The company said this cut organic sales by about 270 basis points and cut operating profit growth by about 530 basis points.
What is the Kenvue deal?
Kimberly-Clark completed its purchase of Kenvue, the maker of Tylenol, on November 2, 2026. The deal is worth roughly $40 billion, and the company expects about $2.1 billion in annual run-rate synergies.
Did the company change its outlook?
No. It reaffirmed its 2026 standalone outlook, including organic sales growth about 100 basis points below category growth and high-single-digit growth in adjusted earnings from continuing operations.
Sources
Reuters, “Kimberly-Clark’s China diaper woes linger as it stands by annual outlook”, November 5, 2026. Zacks, “Kimberly-Clark Q3 Earnings Beat on Lower Interest Costs, Sales Miss”, November 5, 2026.
This article is for general information and education only. It is not legal or financial advice.
